Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 33, 2020-2025, September 1, 1973]
© 1973 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pratt, C. B.
Right arrow Articles by Jackson, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pratt, C. B.
Right arrow Articles by Jackson, R.

Asparaginase in Combination Chemotherapy for Remission Induction of Childhood Acute Lymphocytic Leukemia1

Charles B. Pratt, DeWayne Roberts, Ellen Shanks, Ellen Loehr Warmath and Rudolph Jackson2

Laboratories of Pharmacology [D. R., E. L. W.], Chemotherapy [C. B. P., E. S.], and Hematology [R. J.], St. Jude Children's Research Hospital, Memphis, Tennessee 38101

Forty-six children with acute lymphocytic leukemia in relapse were divided randomly into two groups and treated with combinations of asparaginase (L-asparagine amidohydrolase, EC 3.5.1.1), cytosine arabinoside, and 6-azauridine. The objectives were to improve the 41% incidence of remission induction obtained earlier at this hospital with asparaginase alone and to compare the efficacy and toxicity of combining cytosine arabinoside versus cytosine arabinoside plus 6-azauridine with asparaginase. The first group, 24 children, received 10,000 i.u. of asparaginase per sq m and 300 mg of cytosine arabinoside per sq m on Days 1 and 8 (Schedule A). The second group, 22 children, received identical doses of these two agents plus 15 g of 6-azauridine per sq m on Days 1 and 8 (Schedule B). Complete remission was induced in 15 of the patients on Schedule A and in 13 of those on Schedule B. The median duration of response for the first group was 48 days (range, 14 to > 365); for the second group it was 52 days (range 9 to 177). When compared retrospectively with asparaginase alone, asparaginase combined with cytosine arabinoside increased the incidence but not the duration of remission induction. As determined by simultaneous comparison, there was no advantage in the present study from adding 6-azauridine to the asparaginase-cytosine arabinoside combination.

Thymidine incorporation into DNA by leukemic lymphoblasts was severely inhibited after asparaginase and cytosine arabinoside administration, and remained on the average more than 90% inhibited for over 24 hr.

1 Supported by USPHS Cancer Center Grant CA-08480 and Research Project Grants CA-11148 and CA-12732 from the National Cancer Institure and by ALSAC.

2 Present address: Program Coordinator, Sickle Cell Disease Program, Bldg. 31, 5A-21, NIH, Bethesda, Md. 20014.

Received 2/13/73. Accepted 5/ 9/73.




This article has been cited by other articles:


Home page
J Child NeurolHome page
R. Korinthenberg, A. Schneider, and C. Niemeyer
Central Nervous System Prophylaxis With High-Dose Methotrexate Does Not Give Rise to Significant Electroencephalographic Changes in Children With Acute Lymphoblastic Leukemia
J Child Neurol, June 1, 2002; 17(6): 409 - 412.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1973 by the American Association for Cancer Research.